Last update Aug. 19, 2021
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Dexmedetomidine Hydrochloride in other languages or writings:
Dexmedetomidine Hydrochloride belongs to this group or family:
Main tradenames from several countries containing Dexmedetomidine Hydrochloride in its composition:
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Dexmedetomidine is a selective alpha2-adrenergic receptor agonist, with anxiolytic, analgesic, and sedative properties.
It is used for the sedation of patients in intensive care (intubation) and in medical or surgical procedures, such as caesarean sections.
Administration by intravenous infusion.
Its pharmacokinetic data (large volume of distribution and high percentage of protein binding) explain the negligible passage to breastmilk observed (Yoshimura 2021 and 2017, Nakanishi 2017).
No problems have been observed in infants of mothers to whom it was administered, nor problems with lactation or breastmilk production in lactogenesis II (Wang 2017).
Its tiny excretion in breast milk and its short elimination half-life means that the mother can breastfeed as soon as she is awake and healthy.